Novo Nordisk Taiwan
Location: Taipei, Taiwan
The Position
The Senior Market Access Manager will lead patient centred, public health oriented market access strategies to ensure timely, equitable, and sustainable access to Novo Nordisk treatments across reimbursement and self pay channels in Taiwan. This role integrates access strategy, pricing, HEOR evidence generation, and policy engagement to remove barriers to treatment and improve patient access to innovative therapies.
The incumbent will develop and execute pricing and reimbursement plans and prepare value dossiers and submissions that clearly articulate patient benefit, system value, and public health impact; negotiate with payers to secure fair reimbursement and access pathways; and engage key opinion leaders and medical associations to align strategies with patient and public health priorities.
The role will drive launch readiness by coordinating cross functional efforts, implement post launch lifecycle plans (including reimbursement scope expansions and post listing follow ups), and lead price governance to ensure a sustainable product lifecycle and continued patient access.
Qualifications
We commit to an inclusive recruitment process and equality of opportunity for all our job applicants.
We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic diseases and promote long-term health. Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and treat, prevent, and even cure diseases that affect millions of lives. Because it takes an unordinary approach to drive real, lasting change in health.

We’re not your typical healthcare company. In a modern world of quick fixes, we focus on solutions to defeat serious chronic disease and create long-term health.
Our unordinary mindset is at the heart of everything we do. We seek out new ideas and put people first as we push the boundaries of science, make healthcare more accessible, and work to treat, prevent, and even cure diseases that affect millions of lives. Founded in Denmark in 1923, today we employ more than 77,000 people in 80 offices around the world – all united by our bold purpose to drive change to defeat serious chronic diseases. Want to learn more? Visit www.novonordisk.com.
This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam.
Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please contact Novo Nordisk’s office in the country you live in:
https://www.novonordisk.com/contact-us/find-local-information.html
For other customer complaints, please contact us here:
https://www.novonordisk.com/contact-us.html
Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed.
Comments contained on this site come from members of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn users.
Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and-user-rights/social-media-privacy-disclaimer.html